Literature DB >> 23630205

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.

Elisa Rumi1, Jelena D Milosevic, Ilaria Casetti, Irene Dambruoso, Daniela Pietra, Emanuela Boveri, Marina Boni, Paolo Bernasconi, Francesco Passamonti, Robert Kralovics, Mario Cazzola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23630205     DOI： 10.1200/JCO.2012.46.4370

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

Review 1.  Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.

Authors:  Bulent Kantarcioglu; Isik Kaygusuz-Atagunduz; Ant Uzay; Tayfur Toptas; Tulin Firatli Tuglular; Mahmut Bayik
Journal:  Int J Hematol       Date:  2015-04-02       Impact factor: 2.490

Review 2.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 3.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

4.  BRAF mutation as a novel driver of eosinophilic cystitis.

Authors:  Michael Y Choi; Igor F Tsigelny; Amelie Boichard; Åge A Skjevik; Ahmed Shabaik; Razelle Kurzrock
Journal:  Cancer Biol Ther       Date:  2017-08-22       Impact factor: 4.742

Review 5.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 6.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

7.  Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.

Authors:  Justin Anthony Chen; Yanli Hou; Krishna M Roskin; Daniel A Arber; Charles D Bangs; Linda B Baughn; Athena M Cherry; Mark D Ewalt; Andrew Z Fire; Laure Fresard; Hutton M Kearney; Stephen B Montgomery; Robert S Ohgami; Kathryn E Pearce; Beth A Pitel; Jason D Merker; Jason Gotlib
Journal:  Blood Adv       Date:  2021-09-14

Review 8.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

9.  Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.

Authors:  Ayush Sharma; Naoki Oishi; Rebecca L Boddicker; Guangzhen Hu; Hailey K Benson; Rhett P Ketterling; Patricia T Greipp; Darlene L Knutson; Sara M Kloft-Nelson; Rong He; Bruce W Eckloff; Jin Jen; Asha A Nair; Jaime I Davila; Surendra Dasari; Konstantinos N Lazaridis; N Nora Bennani; Tsung-Teh Wu; Grzegorz S Nowakowski; Joseph A Murray; Andrew L Feldman
Journal:  Blood       Date:  2018-03-28       Impact factor: 25.476

10.  Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Signe Spetalen; Assia Bassarova; Klaus Beiske; Francesca Micci; Sverre Heim
Journal:  Oncotarget       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.